torcetrapib has been researched along with Heart Disease, Ischemic in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (33.33) | 29.6817 |
| 2010's | 2 (66.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Kathiresan, S | 1 |
| Frikke-Schmidt, R; Johannsen, TH; Nordestgaard, BG; Schou, J; Tybjærg-Hansen, A | 1 |
| Lavie, CJ; Milani, RV | 1 |
3 other study(ies) available for torcetrapib and Heart Disease, Ischemic
| Article | Year |
|---|---|
Will cholesteryl ester transfer protein inhibition succeed primarily by lowering low-density lipoprotein cholesterol? Insights from human genetics and clinical trials.
Topics: Anticholesteremic Agents; Cardiovascular Diseases; Cholesterol Ester Transfer Proteins; Female; Humans; Male; Myocardial Ischemia; Quinolines | 2012 |
Genetic inhibition of CETP, ischemic vascular disease and mortality, and possible adverse effects.
Topics: Adult; Aged; Aged, 80 and over; Anticholesteremic Agents; Cardiovascular Diseases; Cholesterol Ester Transfer Proteins; Cohort Studies; Female; Genetic Variation; Genotype; Humans; Male; Middle Aged; Myocardial Ischemia; Quinolines; Risk Factors; Young Adult | 2012 |
Shedding light on high-density lipoprotein cholesterol: the post-ILLUMINATE era.
Topics: Anticholesteremic Agents; Cholesterol Ester Transfer Proteins; Cholesterol, HDL; Cholesterol, LDL; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Myocardial Ischemia; Predictive Value of Tests; Quinolines; Risk Factors | 2008 |